Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Retention in naltrexone implant treatment for opioid dependence.

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):166-9. doi: 10.1016/j.drugalcdep.2010.03.021. Epub 2010 May 31.

PMID:
20570059
2.

Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.

Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G.

Addiction. 2010 Sep;105(9):1669-76. doi: 10.1111/j.1360-0443.2010.03015.x. Epub 2010 Jul 9.

PMID:
20626723
3.

Vivitrex (Alkermes/Cephalon).

Heading CE.

Curr Opin Investig Drugs. 2006 Jan;7(1):81-8. Review.

PMID:
16425675
4.

Sustained-release naltrexone: novel treatment for opioid dependence.

Comer SD, Sullivan MA, Hulse GK.

Expert Opin Investig Drugs. 2007 Aug;16(8):1285-94. Review.

PMID:
17685876
5.

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Lobmaier PP, Kunøe N, Gossop M, Waal H.

CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x. Review.

PMID:
21554565
6.

Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.

Carreño JE, Alvarez CE, Narciso GI, Bascarán MT, Díaz M, Bobes J.

Addict Biol. 2003 Dec;8(4):429-38.

PMID:
14690879
7.

Challenges to antagonist blockade during sustained-release naltrexone treatment.

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, Kristensen Ø, Waal H.

Addiction. 2010 Sep;105(9):1633-9. doi: 10.1111/j.1360-0443.2010.03031.x.

PMID:
20707781
8.

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Gerra G, Fantoma A, Zaimovic A.

J Psychopharmacol. 2006 Nov;20(6):806-14. Epub 2006 Jan 9.

PMID:
16401652
9.

Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.

Waal H, Frogopsahl G, Olsen L, Christophersen AS, Mørland J.

Eur Addict Res. 2006;12(3):138-44.

PMID:
16778434
10.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
11.

Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?

Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD.

Am J Drug Alcohol Abuse. 2006;32(4):503-17.

PMID:
17127538
12.

Extended-release intramuscular naltrexone: a viewpoint by Falk Kiefer.

Kiefer F.

Drugs. 2006;66(13):1752-3. Review. No abstract available.

PMID:
16978039
13.

[Long-acting naltrexone--a new way out of opiate addiction?].

Stavseth LS, Kunøe N, Tanum L.

Tidsskr Nor Laegeforen. 2013 Nov 12;133(21):2231-2. doi: 10.4045/tidsskr.13.1139. Norwegian. No abstract available.

14.

Extended-release intramuscular naltrexone: a viewpoint by Steven Siegel.

Siegel S.

Drugs. 2006;66(13):1752. No abstract available.

PMID:
16978040
15.

Hospital morbidity associated with the natural history of heroin use.

Tait RJ, Hulse GK.

J Opioid Manag. 2008 Sep-Oct;4(5):321-7.

PMID:
19070270
16.

[Alcohol consumption in opioid-dependence patients in treatment with naltrexone].

Ochoa Mangado E, Arias Horcajadas F.

Actas Esp Psiquiatr. 2000 Jul-Aug;28(4):239-49. Spanish.

PMID:
11116795
17.

Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.

Jhugroo A, Ellayah D, Norman A, Hulse G.

J Psychopharmacol. 2014 Aug;28(8):800-3. doi: 10.1177/0269881114528592. Epub 2014 Apr 2.

PMID:
24695742
18.

[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].

Poser W, Ehrenreich H.

Internist (Berl). 1996 Oct;37(10):1061-7; discussion 1067. Review. German. No abstract available.

PMID:
9019453
19.

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG.

J Subst Abuse Treat. 2000 Apr;18(3):277-81.

PMID:
10742642
20.

Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

Hulse GK, Ngo HT, Tait RJ.

Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26.

PMID:
20537615

Supplemental Content

Support Center